Servier Pharmaceuticals is a global pharmaceutical company committed to advancing innovative therapies for patients facing cancer and other serious diseases. Their groundbreaking treatments include VORANIGO® (vorasidenib), the first FDA-approved therapy for Grade 2 IDH-mutant gliomas, and OJEMDA™ (tovorafenib), developed for pediatric patients with relapsed or refractory low-grade glioma.